This one-shot drug cut bad cholesterol by 62%. Why doctors are watching closely
An experimental Eli Lilly gene-editing drug has cut LDL cholesterol by up to 62% in an early trial, raising hopes of a one-time treatment for high-risk heart patients, but larger studies must still prove long-term safety
An experimental Eli Lilly gene-editing drug has cut LDL cholesterol by up to 62% in an early trial, raising hopes of a one-time treatment for high-risk heart patients, but larger studies must still prove long-term safety
